Company Profile

Affect Therapeutics Inc
Profile last edited on: 9/13/22      CAGE: 8WD44      UEI: DBZDN1DH5K35

Business Identifier: Digital substance-use disorder program based upon rewards and motivations with contingency management and digital experience design
Year Founded
2021
First Award
2021
Latest Award
2021
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

520 Broadway 4th Floor
New York, NY 10012
   (703) 623-8113
   info@affecttherapeutics.com
   www.affecttherapeutics.com
Location: Single
Congr. District: 10
County: New York

Public Profile

A nationwide substance use disorder treatment provider, using mobile technology - and a smartphone app - radically to change how alcohol and stimulant addiction recovery is managed, Affect Therapeutics is changing the way the world treats addiction. The firm's data-driven program is personalized - giving members the tools and incentives they need, exactly when and where they need them. The firm develops and offers substance-specific programs, based on in-house research and the latest science. Using contingency management and other types of rewards systems as engagement techniques to drive member retention and better outcomes, the firm's treatment is provided digitally, making it more accessible, more convenient, and less expensive than traditional options. The firm also uses contingency management and other types of rewards systems as engagement techniques to drive member retention and better outcomes. use contingency management and other types of rewards systems as engagement techniques to drive member retention and better outcomes

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2021 1 NIH $309,360
Project Title: Demonstration of a Digital Care Program for Methamphetamine Use Disorder

Key People / Management

  Kristin Muhlner -- CEO

  Saleem Malik

  Renee Mullings

  David K Ricupero -- Business Development

Company News

There are no news available.